Group 1 - Huayi Family Co., Ltd. plans to invest up to 300 million yuan in Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. through a share placement at a price of 4.75 yuan per share, acquiring no more than 63.157895 million shares [2] - After the investment, Huayi Family is expected to hold between 5% and 8.09% of Haihe Pharmaceutical's shares, with its controlling shareholder holding approximately 11.54% of Haihe Pharmaceutical's shares [2] - Haihe Pharmaceutical, established in 2011, focuses on the discovery, development, production, and commercialization of innovative drugs in the oncology field, with three products already commercialized and five in clinical research [2] Group 2 - The investment is seen as a strategic financial investment based on the long-term development potential of innovative drugs, aiming to achieve reasonable financial returns while ensuring stable operations of Huayi Family's main business [3] - The innovative drug market has been rapidly developing, with many pharmaceutical companies achieving significant economic benefits through research and development [3] - Huayi Family aims to explore opportunities in emerging industries through this investment in Haihe Pharmaceutical [3]

Core Viewpoint - The company plans to invest up to RMB 300 million in Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. through a share subscription, aiming to hold at least 5% of the company's equity post-financing [1][3][27] Group 1: Transaction Overview - The share subscription price is set at RMB 4.75 per share, with a maximum subscription of 63.157895 million shares [1][3] - The financing plan involves a rights issue where existing shareholders can subscribe for new shares at a ratio of 2 shares for every 10 shares held [2][19] - The transaction constitutes a related party transaction due to the company's relationship with the controlling shareholder, Shanghai Nanjing Group [1][4] Group 2: Financial and Valuation Aspects - The estimated value of Haihe Pharmaceutical's total equity ranges from RMB 3.41 billion to RMB 4.01 billion based on asset-based valuation methods [20][21] - The company has a solid financial structure, with a low debt-to-asset ratio, indicating that the investment will not adversely affect its financial status [27] Group 3: Business and Market Context - Haihe Pharmaceutical focuses on innovative drug development in the oncology sector, with several products already commercialized or in advanced clinical stages [11][12] - The biopharmaceutical industry is a key growth area in Shanghai, supported by favorable policies and significant market potential [26][27] - The company has established a comprehensive R&D system and has multiple drug pipelines, indicating strong innovation capabilities [12][15]